Staff Writer
Adams Street Partners holds 9,752,058 shares worth about $127 million at the IPO price, Battery Ventures owns 4,812,183 shares worth about $63 million, and C&B Capital owns 774,911 shares worth about $10 million.
Kearny Venture Partners, Novartis Bioventures, Novo A/S, Triathlon Medical Ventures and Venture Investors collectively own 8.4 million shares valued at $143.45 million at the IPO price.
DAG Ventures, Kleiner Perkins Caufield & Byers, Lightspeed Venture Partners, NEA and Northern Light Venture Capital collectively own 26.9 million shares worth $269 million at the IPO price.
Foundation Capital, Neocarta Ventures, Rho Ventures, Scale Venture Partners, WF Holding Company and seven other venture investors collectively own 18.6 million shares worth about $260 million at the IPO price.
Clal Biotechnology Industries owns 9,789,555 shares worth about $137 million at the IPO price.
Advent Life Sciences, Aisling Capital, Amunix, Fidelity, Index Ventures, New Leaf Ventures and Sofinnova Venture Partners own 14,770,487 shares worth about $310 million at the IPO price.
Jaidev Shergill, Capital One’s head of digital venture investing, to head up fintech-focused unit
Round makes private company one of Silicon Valley’s most richly valued
London-based investor, which focuses on U.S. and European healthcare deals, raises $376 million for sixth Bioventures fund
Accelerators across Russia; lower Russian VC spending;